Therapeutic target discovery
Nectin2 identified and investigated as an immunotherapeutic target in prostate cancer.
Employee 0006 - Interactive CV
Dr. Silvia Bressan, PhD
Translational Oncology & Immunotherapy Scientist
Cancer Immunotherapy / Biomarker Discovery / CAR-T / Multi-omics
Connecting biological discoveries with therapeutic strategies and clinically relevant hypotheses.
Profile
PhD-trained translational immunologist with expertise in cancer immunotherapy, biomarker discovery, and multi-omics analysis. Experience integrating patient cohorts, single-cell sequencing, spatial transcriptomics, immune profiling, and computational biology to translate biological discoveries into therapeutic strategies and clinical hypotheses.
Her research spans CAR-T development, immune monitoring, translational oncology, and cross-functional biomarker programs, with experience connecting experimental biology with patient-derived datasets.
Scientific journey
-
Current
Scientist in Translational Oncology and Immunotherapy
2025 - present / Translational Immunotherapy team
Biomarker discovery, patient cohorts, CAR-T therapies, and multi-omics approaches.
-
Fellowship
Marie Sklodowska-Curie Postdoctoral Fellowship
European Commission / 2025-2027
-
Switzerland
Postdoctoral Researcher
2023-2025 / Immuno-Oncology Team, Institute of Oncology Research (IOR), Bellinzona
Andrea Alimonti laboratory / translational immuno-oncology and therapeutic target development.
-
Italy / Switzerland
PhD in Molecular Pharmacology
2020-2023 / University of Padova
Cotutelle PhD thesis in Cancer Biology and Oncology / Universita della Svizzera italiana
Thesis: Identification and targeting of novel immune checkpoint in prostate cancer / Supervisor: Andrea Alimonti
-
Italy
Research Associate
2019-2020 / Veneto Institute of Molecular Medicine (VIMM)
Generation and validation of in-vitro models to study senescence in cancer and aging.
-
Italy
MSc in Pharmaceutical Biotechnologies
2016-2019 / University of Padova
Thesis: Identification and validation of novel targets for senolytic therapy in prostate cancer.
-
Italy
BSc in Biotechnology
2013-2016 / University of Padova
Scientific expertise
- Translational oncology
- Cancer immunotherapy
- Biomarker discovery
- Single-cell transcriptomics
- Spatial transcriptomics
- TCR profiling
- Clinical cohort analysis
- Flow cytometry
- Immune monitoring
- CAR-T development
- Multi-omics analysis
- Cross-functional project leadership
Translational impact
Connecting biological discoveries with therapeutic strategies and clinically relevant hypotheses.
Immunotherapy development
Research contributions spanning CAR-T therapies, therapeutic antibodies, antibody-drug conjugates, and NK-cell-mediated anti-tumor responses.
Biomarker programs
Biomarker discovery integrating clinical cohorts, immune profiling, single-cell approaches, spatial transcriptomics, and computational / multi-omics analysis.
Patents
Co-inventor on two Nectin2-targeting immunotherapy patent applications.
Nectin2 / PSMA antibodies and ADCs
Monospecific and bispecific antibodies and antibody-drug conjugates targeting Nectin2 (CD112) and PSMA. Patent application.
Dual PSMA and Nectin2 targeting
Dual targeting of PSMA and Nectin2 in prostate cancer. Patent application.
Competitive funding
- Marie Sklodowska-Curie Postdoctoral Fellowship / European Commission / 2025-2027
Selected publications
-
Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells
Cancer Cell, 2024 / first / co-first author -
Coagulation factor X promotes resistance to androgen-deprivation therapy in prostate cancer
Cancer Cell, 2024 -
Targeting senescence induced by age or chemotherapy with a polyphenol-rich natural extract improves longevity and healthspan in mice
Nature Aging, 2024 -
Prostate cancer: evading immunity, inspiring therapy
Trends in Cancer, 2026 -
B7-H3 as a therapeutic target in advanced prostate cancer
European Urology, 2022
Ongoing / under review
-
Targeting the Nectin2 for improved CAR T cell therapy in castration-resistant prostate cancer
Original research / Cell / under review -
Gleditsioside E triterpenoid saponin from Gleditsia extract induces senolysis in aging and chemotherapy-induced senescence
Original research / Nature Aging / under revision
Teaching & mentoring
Teaching: Universite PSL / DIU de Medecine Moleculaire en Cancerologie / Topic: Effector and regulatory T lymphocytes.
Mentoring experience across visiting clinical research fellows, master's students, and translational cancer research projects.
Additional
- Founder of the PhD student association at Bios+ Institute
- Special Prize Indaco - startup competition
- Languages: Italian - mother tongue / English - fluent / French - A2
CV
Full scientific CV
Detailed scientific training, publications, research and experience.
One-page profile
Condensed translational oncology and immunotherapy profile.
Let's collaborate
I am open to scientific collaborations across translational oncology, cancer immunotherapy, biomarker development, CAR-T, patient-cohort analysis, and multi-omics research.
Email: silvi@nbulai.com